The University of Southern California Center for Body Computing has teamed with 8 partners to launch a Virtual Care Clinic. The idea with VCC is to create an integrated approach to the use of mobile apps, "virtual" doctors, artificial intelligence, data collection and analysis, as well as diagnostics and wearable sensors to create truly on-demand healthcare.
After disclosing a major restructuring of its medical device business last week, Johnson & Johnson tried to refocus on the future of that group on its annual earnings call. It emphasized doing more deals to acquire platforms for growth, as well as funneling more resources to high revenue growth device groups.
Kyoto University and Panasonic have revealed a novel vital-sign-sensing technology that's based on radar. This enables the system to remotely detect heart rate and heartbeat interval without any sensors being placed on the patient's body. The accuracy of the system is on par with electrocardiographs.
The United Kingdom's National Health Service sees med tech as crucial to addressing healthcare improvements. It's launched a series of 7 trials with several major technology partners designed to test several means of integrating med tech specifically into at-home care for elderly and chronic disease patients.
GlaxoSmithKline has abandoned its plot to win FDA approval for an eczema treatment from Basilea Pharmaceutica, ending a project that could have paid its partner about $72 million plus royalties.
MannKind, decimated by the departure of former co-signer Sanofi, is trying to conserve value in the face of sluggish sales for its inhaled insulin, signing a deal to transfer some of its pipeline to an obscure new company.
South Korea's Celltrion has recruited Medidata to provide eClinical technology as it works to develop copycat versions of the world's top-selling biological treatments.
GlaxoSmithKline and Qualcomm are in talks to create a joint venture to enable GSK to expand into med tech, according to a report by Bloomberg that cites anonymous people knowledgeable of the matter.
Bristol-Myers Squibb, working alongside CytomX Therapeutics, picked a third cancer project in a collaboration that could pay its partner as much as $1.2 billion.
Japanese pharma Takeda and Montreal's enGene have teamed up to develop gastrointestinal gene therapies using the latter company's Gene Pill delivery platform.